MedTrace Logo

Pharmacogenetic Testing Among Home Health Patients

NCT02378220 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2019-09-20

Study results available
· View outcomes & findings →

Summary

Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing. In this open-label trial, a pharmacist will make medication therapy recommendations using YouScript® Personalized Prescribing System for patients who receive genetic testing and standard drug information resources per usual for patients who do not undergo pharmacogenetic testing.

Conditions

  • Adverse Drug Events
  • Adverse Drug Reactions
  • Drug Interaction Potentiation
  • Drug Metabolism, Poor, CYP2D6-RELATED
  • Drug Metabolism, Poor, CYP2C19-RELATED
  • Cytochrome P450 Enzyme Deficiency
  • Cytochrome P450 CYP2D6 Enzyme Deficiency
  • Cytochrome P450 CYP2C9 Enzyme Deficiency
  • Cytochrome P450 CYP2C19 Enzyme Deficiency
  • Cytochrome P450 CYP3A Enzyme Deficiency
  • Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant
  • Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant
  • Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant

Interventions

GENETIC

Pharmacogenetic testing

Pharmacogenetic testing via YouScript® Personalized Prescribing System

Sponsors & Collaborators

  • Harding University

    collaborator OTHER

  • Genelex Corporation

    lead INDUSTRY

Principal Investigators

  • Lindsay Elliott, PharmD · Harding University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-02-29
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02378220 on ClinicalTrials.gov